OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 30 of 33

31 Weight Loss Supplements Considered Potentially Unsafe by the FDA Many weight loss supplements thought unsafe are available via the Internet. Clinicians and patients should optimally be aware of these products and their associated risks. Intervention Side Effects Mechanism of Action 1,3-dimethylamylamine methylhexanamine- DMAA (geranium or pelargonium graveolens extract) Adverse adrenergic side effects (e.g., high blood pressure, myocardial infarction, psychiatric disorders, nervous system disorders, and sudden death) Stimulant, often illegally combined with caffeine Ephedra (ma huang) Adverse adrenergic side effects (e.g., high blood pressure, palpitations, myocardial infarction, stroke, seizure, and sudden death) Ephedrine and pseudoephedrine may reduce hunger Bitter orange (Citrus aurantium) a Chest pain, anxiety, headache, musculoskeletal complaints, increased heart rate, increased blood pressure Contains synephrine that may reduce hunger 2,4 Dinitrophenol (2,4 DNP or DNP) Hyperthermia, tachycardia, diaphoresis, tachypnea, cardiac arrest, and death Uncoupling of mitochondrial oxidative phosphorylation and increased fat metabolism Phenylpropanolamine (PPA) Headache, tremor, insomnia, agitation, palpitations, high blood pressure, cerebral vasculitis, myocardial infarction, and hemorrhagic strokes Synthetic sympathomimetic amine, functionally similar to amphetamine and ephedrine, with hunger suppressant effects

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024